CLINICAL TRIAL: METFORMIN MITIGATION OF ANTIPSYCHOTIC-INDUCED METABOLIC DYSREGUL

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究将评估口服抗高血糖药二甲双胍预防与使用抗精神病药物相关的代谢和生理变化。我们将招募40名患有严重普及性精神疾病(SPMI)的儿童和青少年，他们有很少接触第二代抗精神病药物(SGA)的历史。参与者将接受为期12周的治疗，既可以同时使用二甲双胍和新启动的SGA，也可以只使用新启动的SGA。所有受试者在每次就诊时都将接受健康的生活方式指导。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will evaluate metformin, an oral antihyperglycemic agent, for the prevention of metabolic and physiological changes associated with the use of antipsychotics. We will recruit 40 children and adolescents with a serious pervasive mental illness (SPMI) that have a history of minimal exposure to 2nd generation antipsychotic (SGA) medication. Participants will receive 12 weeks of treatment with either both metformin and the newly initiated SGA, or only the newly initiated SGA. All subjects will receive healthy lifestyle guidance at each visit.